Publications

Filters (1)
May 31, 2014

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid…

Read more
May 30, 2014

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

Read more
April 7, 2014

Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care…

Read more
March 26, 2014

Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of…

Read more
October 23, 2013

A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung…

Read more
March 8, 2013

Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy in LA-SCCHN

Read more